TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26320082

Group type: EXPERIMENTAL
Intervention: Mini-percutaneous nephrolithotomy (mini-PCNL)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Retrograde intrarenal surgery (RIRS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mini-PCNL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 23848034

Group type: EXPERIMENTAL
Intervention: Propofol (Propofol‐allergy group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sevoflurane (Sevoflurane‐allergy group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Propofol (Propofol‐non‐allergy group)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sevoflurane (Sevoflurane‐non‐allergy group)
Number of subjects: 140
Study: 21757914

Group type: EXPERIMENTAL
Intervention: Rebamipide 300 mg daily for 7 weeks
Number of subjects: 132

Group type: COMPARATOR
Intervention: Omeprazole 20 mg daily for 7 weeks
Number of subjects: 132
Study: 19856194

Group type: EXPERIMENTAL
Intervention: Plant stanol esters
Number of subjects: 2
Study: 17012694

Group type: EXPERIMENTAL
Intervention: Participants with mild mental retardation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participants with moderate mental retardation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison subjects without mental retardation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participants with mental retardation (mild and moderate)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Participants with mental retardation
Number of subjects: 150
Study: 15139576

Group type: EXPERIMENTAL
Intervention: Adjustable dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Number of subjects: 1539

Group type: COMPARATOR
Intervention: Fixed dosing of budesonide/formoterol (80/4.5 or 160/4.5 microg), 2 inhalations b.i.d.
Number of subjects: 1539
Study: 10796741

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, bolus 30mg/kg over 15 minutes with a maintenance infusion of 5.4 mg/kg per hour for 23 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, extended maintenance dose from 24 to 48 hours.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, modified regimen.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate, therapy for whiplash injuries.
Number of subjects: 0
Study: 9071954

Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mmol sodium daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 59
Study: 8312208

Group type: EXPERIMENTAL
Intervention: Azithromycin (1g single dose)
Number of subjects: 183
Study: 3707794

Group type: EXPERIMENTAL
Intervention: 1.5% and 2.5% isoflurane in oxygen
Number of subjects: 2

Group type: COMPARATOR
Intervention: 0.75% and 1.75% isoflurane plus 67% nitrous oxide in oxygen
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Nitrous oxide group
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study: 30545921

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (440 mg/m2 days 1-5) / Etoposide (100 mg/m2 days 1-5) during part 2 of consolidation and delayed intensification
Number of subjects: 100

Group type: COMPARATOR
Intervention: Modified Berlin-Frankfurt-Münster regimen (control arm)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 100
Study: 28427550

Group type: EXPERIMENTAL
Intervention: Home-made spacer (HmS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Valved commercial spacer (VCS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups (HmS and VCS)
Number of subjects: 63
Study: 26218256

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (target blood glucose, 4-7 mmol/L) with insulin titration based on blood glucose values and rate of change.
Number of subjects: 92
Study: 23706063

Group type: EXPERIMENTAL
Intervention: Triticum monococcum (Tm) - 2.5 grams
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rice (as reference atoxic protein) - 2.5 grams
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amygluten (as reference toxic protein) - 2.5 grams
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triticum monococcum (Tm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amygluten
Number of subjects: 12
Study: 21516545

Group type: EXPERIMENTAL
Intervention: Instructed emotion regulation (increase and decrease instructions)
Number of subjects: 0
Study: 18469350

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (5.2 g daily for 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Olive oil placebo (for 12 weeks)
Number of subjects: 46
Study: 16517955

Group type: EXPERIMENTAL
Intervention: Daily oral 800 IU vitamin E and 500 mg vitamin C (n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: B-group vitamins (5 mg folic acid, 5 mg vitamin B(2), 50 mg vitamin B(6), and 0.4 mg of vitamin B(12); n = 24)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both vitamins together (n = 24)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No supplementation (control group; n = 24)
Number of subjects: 96
Study: 12706363

Group type: EXPERIMENTAL
Intervention: Tumour excision plus tamoxifen
Number of subjects: 136

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 136
Study: 10921768

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily) with salmeterol placebo
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Inhaled salmeterol (100 microg daily) with montelukast placebo
Number of subjects: 1200
Study: 8725733

Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg/day)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no antiplatelet medication)
Number of subjects: 115
Study: 1533312

Group type: EXPERIMENTAL
Intervention: Pulsed intra-nasal mupirocin ointment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3890132

Group type: EXPERIMENTAL
Intervention: L-carnitine, 2 g i.v. three times per week
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 28
Study: 29369674

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) comparing their drinking and perceived norms to actual drinking rates for same sex veterans
Number of subjects: 784

Group type: COMPARATOR
Intervention: Feedback about same sex veteran video game play (control condition)
Number of subjects: 784
Study: 29328027

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (recombinant growth hormone injection once weekly for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26651472

Group type: EXPERIMENTAL
Intervention: TEXT intervention (bidirectional text messaging)
Number of subjects: 63

Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 63
Study: 23207959

Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg twice daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Solifenacin (5 mg once daily)
Number of subjects: 109
Study: 22041946

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin therapy
Number of subjects: 10041

Group type: COMPARATOR
Intervention: Control treatment (aspirin alone)
Number of subjects: 10041
Study: 17625501

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg orally twice daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 17135729

Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (0.9 pmol/kg/min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous GLP-1 (0.9 pmol/kg/min) with a protein preload (400 ml protein shake)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preload of 400 ml water or 400 ml protein shake
Number of subjects: 12
Study: 14749629

Group type: EXPERIMENTAL
Intervention: Abdominal sacral colpopexy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Vaginal sacrospinous colpopexy
Number of subjects: 95
Study: 11152378

Group type: EXPERIMENTAL
Intervention: Guanabenz (oral administration for 2 weeks)
Number of subjects: 11
Study: 9461727

Group type: EXPERIMENTAL
Intervention: Allergovit immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no desensitization)
Number of subjects: 0
Study: 7530963

Group type: EXPERIMENTAL
Intervention: Tricyclic drugs
Number of subjects: 104
Study: 3395666

Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation B
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation C
Number of subjects: 12
Study: 30281041

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 0
Study: 27741006

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (ELC)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed laparoscopic cholecystectomy (DLC)
Number of subjects: 86
Study: 23980910

Group type: EXPERIMENTAL
Intervention: Nonprescriptive dietary intervention based on UK dietary guidelines
Number of subjects: 262
Study: 22222193

Group type: EXPERIMENTAL
Intervention: LNG‐IUS12
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: LNG‐IUS16
Number of subjects: 738

Group type: COMPARATOR
Intervention: Mirena
Number of subjects: 738
Study: 20696154

Group type: EXPERIMENTAL
Intervention: 100 μg GMZ2 vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rabies control vaccine
Number of subjects: 40
Study: 18240099

Group type: EXPERIMENTAL
Intervention: Echinaforce tablets
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Echinaforce Junior tablets
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Echinacea sore throat spray
Number of subjects: 3
Study: 16548353

Group type: EXPERIMENTAL
Intervention: Raw rhubarb (RR) 9 g/d
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 40
Study: 12834313

Group type: EXPERIMENTAL
Intervention: Immunoglobulin at doses of 50 mg/kg, 250 mg/kg, or 500 mg/kg weekly from day ‐7 to day 100 after transplantation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Immunoglobulin
Number of subjects: 200
Study: 11728260

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 18895

Group type: EXPERIMENTAL
Intervention: Lisinopril with ASA
Number of subjects: 18895

Group type: EXPERIMENTAL
Intervention: Lisinopril without ASA
Number of subjects: 18895

Group type: EXPERIMENTAL
Intervention: ASA and Lisinopril
Number of subjects: 18895
Study: 8784653

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1531677

Group type: EXPERIMENTAL
Intervention: Albuterol and ipratropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipratropium bromide alone
Number of subjects: 0
Study: 6374684

Group type: EXPERIMENTAL
Intervention: Proxyphylline (2400 mg/day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline (800 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31278225

Group type: EXPERIMENTAL
Intervention: Single bolus of IV ondansetron at a dose of 0.2 mg/kg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 29490302

Group type: EXPERIMENTAL
Intervention: Tamoxifen followed by exemestane (tamoxifen‐exemestane group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Exemestane (exemestane‐only group)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 27291501

Group type: EXPERIMENTAL
Intervention: Testosterone solution 2% (TS)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 25223208

Group type: EXPERIMENTAL
Intervention: Ocular draping
Number of subjects: 262

Group type: COMPARATOR
Intervention: No ocular draping
Number of subjects: 262
Study: 22849413

Group type: EXPERIMENTAL
Intervention: Accused of cheating (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not accused of cheating (n = 15)
Number of subjects: 30
Study: 20522464

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg for 5-12 years, 10 mg for >12 years)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Montelukast and Placebo (both groups)
Number of subjects: 117
Study: 18525261

Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: 6-week antiretroviral therapy interruption
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antiretroviral therapy interruption extended to viral set point
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Resumption of antiretroviral therapy
Number of subjects: 36
Study: 15996071

Group type: EXPERIMENTAL
Intervention: 150 mg IL-1Ra
Number of subjects: 14
Study: 12499348

Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with meat
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with milk
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: School-based feeding intervention with nonanimal-source foods
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 200
Study: 10230262

Group type: EXPERIMENTAL
Intervention: EMA serum
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: EMA saliva
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 130
Study: 9569804

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy with local metronidazole administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonsurgical periodontal therapy without local metronidazole administration
Number of subjects: 10
Study: 1871705

Group type: EXPERIMENTAL
Intervention: Salbutamol (200 or 400 micrograms)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3877292

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 20
Study: 31389049

Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-A
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-B
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Rhinovirus species RV-C
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Overall rhinovirus types
Number of subjects: 547

Group type: COMPARATOR
Intervention: Reported respiratory symptoms
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Median ages at illness onset
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Median PCR cycle threshold values
Number of subjects: 547

Group type: COMPARATOR
Intervention: Association between RV species and disease severity
Number of subjects: 547
Study: 29196963

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Letrozole (LET) 2.5 mg/day
Number of subjects: 54
Study: 26948184

Group type: EXPERIMENTAL
Intervention: 200-mg mifepristone followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Number of subjects: 100

Group type: COMPARATOR
Intervention: Identical placebo followed by 400-mcg misoprostol vaginally 4-6h prior to D&E
Number of subjects: 100
Study: 25304996

Group type: EXPERIMENTAL
Intervention: Public Reporting (PR) intervention group
Number of subjects: 34815

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34815
Study: 21749167

Group type: EXPERIMENTAL
Intervention: Experimental Treatment Group (ETG): plaque control and root planing plus amoxicillin and metronidazole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control Treatment Group (CTG): plaque control instructions, supragingival scaling, and two placebos
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Experimental Treatment Group (ETG)
Number of subjects: 165
Study: 20729710

Group type: EXPERIMENTAL
Intervention: Imiquimod cream applied three times a week for 4 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo cream applied three times a week for 4 months
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Open-label imiquimod treatment for a further 4 months after initial treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Overall follow-up after treatment
Number of subjects: 64
Study: 22300431

Group type: EXPERIMENTAL
Intervention: More intensive belatacept regimen (MI)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Less intensive belatacept regimen (LI)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 543
Study: 15749145

Group type: EXPERIMENTAL
Intervention: AF1996 cohort (N = 29,036)
Number of subjects: 60116

Group type: EXPERIMENTAL
Intervention: AF2000 cohort (N = 31,080)
Number of subjects: 60116

Group type: EXPERIMENTAL
Intervention: Male recruits ages 25‐29 in AF1996
Number of subjects: 60116

Group type: EXPERIMENTAL
Intervention: Male recruits ages 25‐29 in AF2000
Number of subjects: 60116

Group type: COMPARATOR
Intervention: AF1996 cohort compared to BRFSS 1996
Number of subjects: 60116

Group type: COMPARATOR
Intervention: AF2000 cohort compared to BRFSS 2000
Number of subjects: 60116
Study: 12377682

Group type: EXPERIMENTAL
Intervention: Specialists
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Generalists
Number of subjects: 288
Study: 9814491

Group type: EXPERIMENTAL
Intervention: Isoproterenol (10(-6) mol/L)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Submaximal exercise
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ethanol dilution for local blood flow
Number of subjects: 48
Study: 8123955

Group type: EXPERIMENTAL
Intervention: Telephone contact intervention (weekly calls from a healthcare professional during the first month of drug therapy)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 81
Study: 2510286

Group type: EXPERIMENTAL
Intervention: Rioprostil + Aspirin
Number of subjects: 166

Group type: COMPARATOR
Intervention: Aspirin + Placebo
Number of subjects: 166
Study: 5135250

Group type: EXPERIMENTAL
Intervention: mefruside
Number of subjects: 45

Group type: COMPARATOR
Intervention: frusemide
Number of subjects: 45
Study: 31558040

Group type: EXPERIMENTAL
Intervention: SBS app (experimental group)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 265
Study: 30118448

Group type: EXPERIMENTAL
Intervention: SRT-derived intervention
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 45
Study: 28836809

Group type: COMPARATOR
Intervention: TOPS-F
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: TOPS-TO
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: TOPS-F and TOPS-TO
Number of subjects: 152
Study: 25467738

Group type: EXPERIMENTAL
Intervention: Modified quadrangular Le Fort I osteotomy (MQLI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional Le Fort I osteotomy (LFI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both MQLI and LFI
Number of subjects: 40
Study: 23561230

Group type: EXPERIMENTAL
Intervention: intensive psychotherapy for depression (n = 62)
Number of subjects: 106

Group type: COMPARATOR
Intervention: collaborative care (n = 44)
Number of subjects: 106
Study: 21379571

Group type: EXPERIMENTAL
Intervention: Ascent profiles during the expedition to high altitudes (up to 6865 m)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxygen saturation (SpO₂) and hematocrit assessments
Number of subjects: 28
Study: 19004198

Group type: EXPERIMENTAL
Intervention: Acupuncture at Jiaji L4‐S1, Waiqiu (GB 36), Weizhong (BL 40), Xiaxi (GB 43) plus intervention injection of Gegensu Zhusheye (Puerarin Injectio)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine acupuncture combined with injection of Gegensu Zhusheye (Puerarin Injectio) into Ashi points
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16600840

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention and referral to a nutritionist (from the beginning of olanzapine treatment in 9 patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention and referral to a nutritionist (from the 9th week of therapy in 8 patients)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Psychoeducational approach from the beginning
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Higher mean dosages of olanzapine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Poor dietary compliance
Number of subjects: 18
Study: 12635791

Group type: EXPERIMENTAL
Intervention: Internal fixation using 2 von Bahr screws (n = 53)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bipolar Variokopf prosthesis (n = 47)
Number of subjects: 100
Study: 10908256

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 8970048

Group type: EXPERIMENTAL
Intervention: 6 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 12 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 24 mg betamethasone + 4 cm3 of 1% lidocaine
Number of subjects: 75
Study: 1420996

Group type: EXPERIMENTAL
Intervention: IL-1ra (1 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IL-1ra (10 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: IL-1ra (1 mg/kg and 10 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: IL-1ra
Number of subjects: 25
Study: 4047702

Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30575804

Group type: EXPERIMENTAL
Intervention: Teprotumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29921561

Group type: EXPERIMENTAL
Intervention: Simultaneous intervention
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Sequential intervention
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control (stress and sleep contact)
Number of subjects: 212